DrugPatentWatch Database Preview

NASONEX Drug Profile

« Back to Dashboard

Which patents cover Nasonex, and when can generic versions of Nasonex launch?

Nasonex is a drug marketed by Merck Sharp Dohme and is included in one NDA.

The generic ingredient in NASONEX is mometasone furoate. There are thirty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

Summary for NASONEX

US Patents:	0
Applicants:	1
NDAs:	1
Suppliers / Packagers:	3
Bulk Api Vendors:	62
Clinical Trials:	45
Patent Applications:	4,619
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for NASONEX
Drug Sales Revenues:	Drug sales revenues for NASONEX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NASONEX
DailyMed Link:	NASONEX at DailyMed

See drug prices for NASONEX

See drug sales revenues for NASONEX

Recent Clinical Trials for NASONEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Washington University School of Medicine	Phase 4
EMS	Phase 3
Association Asthma, Bulgaria	Phase 4

See all NASONEX clinical trials

Recent Litigation for NASONEX

Identify potential future generic entrants

District Court Litigation

Case Name	Date
MERCK SHARP & DOHME CORP. v. APOTEX INC.	2015-04-02
Merck Sharp & Dohme Corp. v. Amneal Pharmaceuticals LLC	2015-03-20
Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc.	2014-07-03

See all NASONEX litigation

Pharmacology for NASONEX

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Synonyms for NASONEX

(11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate

(11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione

(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate

(9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate

[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloranyl-17-(2-chloranylethanoyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate

[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate

04201GDN4R

11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate

2-furancarboxylic acid [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloro-1-oxoethyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester

83919-23-7

9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate

9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)

919M237

A840685

AB2000407

AC-941

AC1L9AZS

AK163902

AKOS015994732

AN-15438

Asmanex

Asmanex HFA

Asmanex Twisthaler

BC228151

BDBM50148733

BPBio1_000424

BRD-K60640630-001-03-7

BRD-K60640630-001-11-0

BRN 4340538

BSPBio_000384

C07817

C27H30Cl2O6

CAS-83919-23-7

CCG-220572

CHEBI:47564

CHEMBL1161

CS-2389

D00690

Danitin

DSSTox_CID_3333

DSSTox_GSID_23333

DSSTox_RID_76981

DTXSID4023333

Ecural

Elocone

Elomet

Flumeta

HMS1569D06

HMS2096D06

HMS2235I14

HMS3713D06

HY-13693

KS-00000SPL

KS-1275

LAS 41002

M2354

MLS002153879

MolPort-003-849-257

Mometasone 17-(2-furoate)

mometasone 17-furoate

mometasone furancarboxylate

mometasone furoate

Mometasone furoate (JAN/USP)

Mometasone furoate [USAN:USP:JAN]

Mometasone Furoate Impurity G

MOMETASONE FUROATE MONOHYDRATE

Mometasone furoate, >=98% (HPLC)

Mometasone furoate, European Pharmacopoeia (EP) Reference Standard

Mometasone Furoate, Pharmaceutical Secondary Standard; Certified Reference Material

Mometasone furoate, United States Pharmacopeia (USP) Reference Standard

Monovo

NCGC00016950-01

NCGC00179578-01

NCGC00179578-03

NCGC00179578-04

Nosorex

NSC-746171

NSC746171

Ovixan

Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)-

Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)-

Prestwick_924

Prestwick0_000572

Prestwick1_000572

Prestwick2_000572

Prestwick3_000572

Q-101380

Rimelon

s1987

Sch 32088

Sch-32088

SCHEMBL4568

Sinuva

SMR001233233

SPBio_002603

SR-01000841209

SR-01000841209-2

ST24048112

TL8005500

Tox21_110705

Tox21_110705_1

UNII-04201GDN4R

WOFMFGQZHJDGCX-ZULDAHANSA-N

ZINC3938677

Paragraph IV (Patent) Challenges for NASONEX

Tradename	Dosage	Ingredient	NDA	Submissiondate
NASONEX	SPRAY, METERED;NASAL	mometasone furoate	020762	2009-08-07

US Patents and Regulatory Information for NASONEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	NASONEX	mometasone furoate	SPRAY, METERED;NASAL	020762-001	Oct 1, 1997	AB	RX	Yes	Yes

Expired US Patents for NASONEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	NASONEX	mometasone furoate	SPRAY, METERED;NASAL	020762-001	Oct 1, 1997
Merck Sharp Dohme	NASONEX	mometasone furoate	SPRAY, METERED;NASAL	020762-001	Oct 1, 1997
Merck Sharp Dohme	NASONEX	mometasone furoate	SPRAY, METERED;NASAL	020762-001	Oct 1, 1997
Merck Sharp Dohme	NASONEX	mometasone furoate	SPRAY, METERED;NASAL	020762-001	Oct 1, 1997